Cardiac amyloidosis is not a single disease: a multiparametric comparison between the light chain and transthyretin forms

被引:2
|
作者
Neculae, Gabriela [1 ,2 ]
Adam, Robert [1 ,2 ]
Jercan, Andreea [2 ,3 ]
Badelita, Sorina [3 ]
Tjahjadi, Catherina [4 ]
Draghici, Mirela [5 ]
Stan, Claudiu [6 ]
Bax, Jeroen J. [4 ]
Popescu, Bogdan A. [1 ,2 ]
Marsan, Nina Ajmone [4 ]
Coriu, Daniel [2 ,3 ]
Jurcut, Ruxandra [7 ,8 ]
机构
[1] Prof Dr CC Iliescu Emergency Inst Cardiovasc Dis, Expert Ctr Rare Cardiovasc Dis, Bucharest, Romania
[2] Carol Davila Univ Med & Pharm, Bucharest, Romania
[3] Fundeni Clin Inst, Dept Hematol, Bucharest, Romania
[4] Leiden Univ, Med Ctr, Dept Cardiol, Leiden, Netherlands
[5] Fundeni Clin Inst, Dept Neurol, Bucharest, Romania
[6] Fundeni Clin Inst, Dept Nucl Med, Bucharest, Romania
[7] Carol Davila Univ Med & Pharm, Expert Ctr Rare Cardiovasc Dis, Prof Dr CC Iliescu Emergency Inst Cardiovasc Dis, Bucharest, Romania
[8] Carol Davila Univ Med & Pharm, Euroecholab, Prof Dr CC Iliescu Emergency Inst Cardiovasc Dis, Bucharest, Romania
来源
ESC HEART FAILURE | 2024年 / 11卷 / 05期
关键词
AL amyloidosis; ATTR amyloidosis; Cardiac amyloidosis; Diagnostic score; Myocardial deformation; CONSENSUS DOCUMENT; AL AMYLOIDOSIS; DIAGNOSIS; ECHOCARDIOGRAPHY; STANDARDIZATION; DYSFUNCTION; BIOMARKERS; PROGNOSIS;
D O I
10.1002/ehf2.14852
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims Systemic amyloidosis represents a heterogeneous group of diseases resulting from amyloid fibre deposition. The purpose of this study is to establish a differential diagnosis algorithm targeted towards the two most frequent subtypes of CA. Methods and results We prospectively included all consecutive patients with ATTR and AL evaluated between 2018 and 2022 in two centres in a score derivation cohort and a different validation sample. All patients had a complete clinical, biomarker, electrocardiographic, and imaging evaluation. Confirmation of the final diagnosis with amyloid typing was performed according to the current international recommendations. The study population included 81 patients divided into two groups: ATTR (group 1, n = 32: 28 variant and 4 wild type) and AL (group 2, n = 49). ATTR patients were younger (50.7 +/- 13.9 vs. 60.2 +/- 7.3 years, P = 0.0001), and significantly different in terms of NT-proBNP [ATTR: 1472.5 ng/L (97-4218.5) vs. AL 8024 ng/L (3058-14 069) P = 0.001], hs-cTn I [ATTR: 10 ng/L (4-20) vs. AL 78 ng/L (32-240), P = 0.0002], GFR [ATTR 95.4 mL/min (73.8-105.3) vs. AL: 68.4 mL/min (47.8-87.4) P = 0.003]. At similar left ventricular (LV) wall thickness and ejection fraction, the ATTR group had less frequently pericardial effusion (ATTR: 15% vs. AL: 33% P = 0.0027), better LV global longitudinal strain (ATTR: -13.1% +/- 3.5 vs. AL: -9.1% +/- 4.3 P = 0.04), RV strain (ATTR: -21.9% +/- 6.2 vs. AL: -16.8% +/- 6 P = 0.03) and better reservoir function of the LA strain (ATTR: 22% +/- 12 vs. AL: 13.6% +/- 7.8 P = 0.02). Cut-off points were calculated based on the Youden method. We attributed to 2 points for parameters having an AUC > 0.75 (NT-proBNP AUC 0.799; hs-cTnI AUC 0.87) and 1 point for GFR (AUC 0.749) and TTE parameters (GLS AUC 0.666; RV FWS AUC 0.649, LASr AUC 0.643). A score of equal or more than 4 points has been able to differentiate between AL and ATTR (sensitivity 80%, specificity 62%, AUC = 0.798). The differential diagnosis score system was applied to the validation cohort of 52 CA patients showing a sensitivity of 81% with specificity of 77%. Conclusions CA is a complex entity and requires extensive testing for a positive diagnosis. This study highlights a series of non-invasive checkpoints, which can be useful in guiding the decision-making process towards a more accurate and rapid differential diagnosis.
引用
收藏
页码:2481 / +
页数:977
相关论文
共 50 条
  • [41] Temporal trends and outcomes of heart failure patients between light-chain cardiac amyloidosis and transthyretin cardiac amyloidosis: insights from the national inpatient sample database
    Gandhi, K.
    Moras, E.
    Correa, A.
    Mahmood, K.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [42] Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage
    Law, Steven
    Petrie, Aviva
    Chacko, Liza
    Cohen, Oliver C.
    Ravichandran, Sriram
    Gilbertson, Janet A.
    Rowczenio, Dorota
    Wechalekar, Ashutosh
    Martinez-Naharro, Ana
    Lachmann, Helen J.
    Whelan, Carol J.
    Hutt, David F.
    Hawkins, Philip N.
    Fontana, Marianna
    Gillmore, Julian D.
    ESC HEART FAILURE, 2020, 7 (06): : 3942 - 3949
  • [43] Clinical characteristics, natural history and prognostic factors in patients with light chain and transthyretin cardiac amyloidosis
    Barge Caballero, G.
    Vazquez-Garcia, R.
    Barge-Caballero, E.
    Couto-Mallon, D.
    Paniagua-Martin, M. J.
    Barriales-Villa, R.
    Pinon-Esteban, P.
    Bouzas-Mosquera, A.
    Pombo-Otero, J.
    Deben-Ariznavarreta, G.
    Vazquez-Rodriguez, J. M.
    Crespo-Leiro, M.
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 125 - 125
  • [44] ELEVATION OF HEPATOCYTE GROWTH FACTOR CAN INDICATE CARDIAC INVOLVEMENT IN LIGHT CHAIN AND TRANSTHYRETIN AMYLOIDOSIS
    Zhang, Kathleen
    Kraja, Aldi
    Miao, Jennifer
    Tomasek, Kelsey
    Su, Yan Ru
    Lenihan, Daniel
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 767 - 767
  • [45] Heart-to-femoral diaphysis ratio: an alternative method to differentiate cardiac transthyretin amyloidosis from light chain amyloidosis
    Unceta Barrenechea, A. Roteta
    Parra Rina, M.
    Saker Diffalah, Y.
    Tardin Cardoso, L.
    Nogueira Souto, D.
    Razola Alba, P.
    Delgado Castro, M.
    Escalera Temprado, T.
    Aibar Arregui, M.
    Melero Polo, J.
    Revilla Marti, P.
    Gracia Gutierrez, A.
    Bueno Juana, E.
    Moreno Gazquez, I.
    Menao Guillen, S.
    Perez Palacios, R.
    Abengochea Quilez, L.
    Atienza Ayala, S.
    Lahuerta Pueyo, C.
    Andres Gracia, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S221 - S221
  • [46] Beyond amyloidosis: a case of cardiac light chain deposition disease
    Vergaro, G. Giuseppe
    Pasanisi, E. M.
    Passino, C.
    Valleggi, A.
    Mirizzi, G.
    Paolicchi, A.
    Pucci, A.
    Bernazzali, S.
    Buda, G.
    Emdin, M.
    EUROPEAN JOURNAL OF HEART FAILURE, 2015, 17 : 33 - 34
  • [47] Cardiac Troponin in Patients With Light Chain and Transthyretin Cardiac Amyloidosis JACC: CardioOncology State-of-the-Art Review
    De Michieli, Laura
    Cipriani, Alberto
    Iliceto, Sabino
    Dispenzieri, Angela
    Jaffe, Allan S.
    JACC: CARDIOONCOLOGY, 2024, 6 (01): : 1 - 15
  • [48] Mechanisms of left ventricular systolic dysfunction in light chain amyloidosis: a multiparametric cardiac MRI study
    Katznelson, Ethan
    Jerosch-Herold, Michael
    Cuddy, Sarah A. M.
    Clerc, Olivier F.
    Benz, Dominik C.
    Taylor, Alexandra
    Rao, Shivani
    Kijewski, Marie Foley
    Liao, Ronglih
    Landau, Heather
    Yee, Andrew J.
    Ruberg, Frederick L.
    Di Carli, Marcelo F.
    Falk, Rodney H.
    Kwong, Raymond Y.
    Dorbala, Sharmila
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2024, 11
  • [49] DAYS ALIVE AND OUTSIDE OF HOSPITAL IS GREATER AMONG PATIENTS WITH TRANSTHYRETIN CARDIAC AMYLOIDOSIS COMPARED TO LIGHT CHAIN CARDIAC AMYLOIDOSIS AFTER INITIAL HOSPITALIZATION
    Rubin, Jonah
    Teruya, Sergio
    Helmke, Stephen
    Alvarez, Julissa
    Maurer, Mathew
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 925 - 925
  • [50] Impact of Left Ventricular Diastolic Function on Occurrence of Cardiovascular Events in Cardiac Amyloidosis: Comparison of Myocardial Biopsy-Proven Transthyretin With Immunoglobulin Light Chain Amyloidosis
    Nakahashi, Takuya
    Arita, Takeshi
    Yamagishi, Masakazu
    CIRCULATION, 2013, 128 (22)